HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells

Aberrant epigenetic regulation is closely associated with drug tolerance, an early step in the acquisition of drug resistance. We previously reported that a pioneer transcriptional factor (also called an epigenetic initiator) rapidly induced by osimertinib, a third-generation epidermal growth factor...

Full description

Bibliographic Details

Published in:	Biochemistry and Biophysics Reports
Main Authors:	Hanbing Lyu, Akihiko Ishimura, Ryusuke Suzuki, Khurelsukh Buyanbat, Gerelsuren Batbayar, Makiko Meguro-Horike, Shin-ichi Horike, Seiji Yano, Takeshi Suzuki
Format:	Article
Language:	English
Published:	Elsevier 2025-06-01
Subjects:	HDAC5 LMK235 Lung cancer EGFR-TKI Osimertinib Drug resistance
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405580825001037